|
|
|
Welcome
to LymphomaLinks,
your monthly source of lymphoma news, research
updates, clinical trials and events sponsored by
The Leukemia & Lymphoma Society (LLS). For
even more information, regularly visit
LLS's Patient
Services and Disease
Information Web
sections. | |
 |
|
Latest Lymphoma
News
Protein
Complex Key in Avoiding DNA Repair Mistakes,
Cancer
As the body creates antibodies to
fight invaders, a three-protein DNA repair
complex called MRN is crucial for a normal
gene-shuffling process to proceed properly,
University of Michigan research shows. David
O. Ferguson, M.D., Ph.D., the study's senior
recently was awarded funding for five years as a
Leukemia & Lymphoma Society
Scholar. ::READ MORE
NEWS::
| |
|
 |
LLS
Features
::READ
MORE::
.....................................................................................................................................
Research
Roundup
::READ
MORE::
.....................................................................................................................................
IRC Question of
the Month
:: READ
MORE::
| |
|
|
Inspirational
Stories
 Learn how individuals touched
by blood cancer cope. LLS's LifeMosaic Web feature offers
hundreds of inspiring stories by patients and families. Read
them or submit your own. This
month, meet Linda. |
Here to
Help
For
even more information, regularly visit the LLS
Web site,
www.LLS.org
,
where many of our education programs are
archived free of charge for convenient access
24/7.
If you haven't found what you're
looking for in LymphomaLinks , please
call our Information Resource Center (IRC) to
speak with trained information specialists. IRC
staff are available Monday through Friday, 9
a.m. to 6 p.m. ET, toll free at (800) 955-4572;
email
infocenter@lls.org
;
or click the "Live Patient Help" button on
the www.LLS.org
homepage.
| |
|
|
Commentary
Deborah Banker, Ph.D., shares more
news on immunotherapies and
biomarkers.
Clinical
Trials
We
invite you to use
our LLS-supported TrialCheck®
Web site, a clinical trial search service
that offers patients and caregivers immediate
access to listings of
all lymphoma clinical trials. Answer
just a few simple questions and a list of
available clinical trials related to your cancer
will appear in an easy to read list of search
results.
You may also want to visit the
National Cancer Institute's Cancer
Trials Support Unit, providing resources and
information on phase III cancer treatment trials
supported by the National Cancer
Institute
. ::SELECTED TRIALS::
Newsfeeds &
Podcasts
Now you can get
RSS Feeds and Podcasts from LLS.
::CLICK HERE TO SIGN
UP::
Free
eNewsletters
Free LLS
eNewsletters deliver the latest information on
research and treatment options, patient services
programs and fundraising events.
:: CLICK HERE TO SIGN
UP::
| | | |
| 
| | | |
|
|
|
Young
Leukemia and Lymphoma Patients Live Longer Today
than in Years Past
A new analysis has
found that adolescents and young adults who were
recently diagnosed with blood-related cancers
have better long-term survival rates than those
who were diagnosed in the 1980s.
Bcl6
Gene Sculpts Helper T Cell to Boost Antibody
Production
Expression of a single gene
programs an immune system helper T cell that
fuels rapid growth and diversification of
antibodies in a cellular structure implicated in
autoimmune diseases and development of B cell
lymphoma, scientists at The University of Texas
M. D. Anderson Cancer Center reported July 23 in
Science Express, the advance online publication
of the journal Science.
The work is
supported by a research grant from The Leukemia
and Lymphoma Society. Researcher Chen Dong,
Ph.D., is a Leukemia and Lymphoma Society
Scholar.
> Back to
the
top
| |
|
Emerging
Therapies in NHL: Understanding Your
Options
Register now for this free
telephone education program. This program
will take place on Tuesday, September 22, 2009
from 12-1:30 pm ET and the featured speaker is
Andrew D. Zelenetz, MD, PhD, Chief ,
Lymphoma Service, Division of
Hematology/Oncology, Department of Medicine,
Memorial Sloan-Kettering Cancer Center, New
York, NY. Participants will have the opportunity
to ask the presenter questions during the
program.
Treating
Uncommon Lymphomas: Dialogue With an Expert on
T-Cell, MALT, and Waldenström
Macroglobulinemia
Register now for this
free telephone education program. This
program will take place on Wednesday, October
14, 2009 from 12-1 pm ET and the featured
speaker is Richard R. Furman, MD, Assistant
Professor , Center for Lymphoma and
Myeloma, Division of Hematology and Oncology,
Weill Medical College of Cornell University ,
New York, NY. Participants will have the
opportunity to ask the presenter questions
during the program.
My
Personal Lymphoma Journey
This unique
interactive Web program follows the stories and
experiences of lymphoma survivors, including a
new story of a follicular lymphoma survivor. The
guest physician is John P. Leonard, MD, of Weill
Medical College of Cornell University/New
York-Presbyterian Hospital, New York, NY. We
hope this program helps you to learn more about
the lymphoma journey, and resources that are
available to you and other lymphoma
survivors.
My
Clinical Trials Journey
This personalized
and interactive program follows the stories and
experiences of three cancer survivors who have
participated in clinical trials, including a
lymphoma survivor. Their stories of hope and
determination are compelling. Ann Pirro,
Physician's Assistant at Queens Medical Center,
Fresh Meadows, NY, provides expert insights
along the
way.
LLS
Advocacy
LLS's
advocacy team represents the needs of cancer
patients and their families in Washington,
DC and state capitals throughout the United
States. We need your help. Join our
Advocates Network and make your voice heard.
TAKE
ACTION: Urge Your Representative to Support
Increased Cancer Research Funding - Tell
your elected officials that to win the war on
cancer, they need to fund the war on
cancer!
We'd Like to Hear from
You!
Please give us your feedback
after you read an LLS Publication by completing
our evaluation:
LLS
Disease & Treatment Publications - Survey
for Patients, Family and Friends
Nos gustaría saber sus
opiniones
Por favor denos sus
comentarios después de leer una publicación de
LLS completando nuestra evaluación:
Publicaciones
de LLS sobre enfermedades y tratamiento:
Encuesta para pacientes, familiares y
amigos
LLS Blog
Learn the many ways you can help advance the
LLS mission, including making a donation.
Find
out more about our other
eNewsletters.
> Back to the
top
| |
|
Rituximab plus short-duration chemotherapy
followed by Yttrium-90 Ibritumomab tiuxetan as
first-line treatment for patients with
follicular non-Hodgkin lymphoma: a phase II
trial of the Sarah Cannon Oncology Research
::READ
MORE::
Placebo-Controlled Phase III Trial of
Patient-Specific Immunotherapy with
Mitumprotimut-T and Granulocyte-Macrophage
Colony-Stimulating Factor After Rituximab in
Patients with Follicular Lymphoma ::READ
MORE::
Long term outcome of localized aggressive
non-Hodgkin lymphoma treated with a short weekly
chemotherapy regimen (doxorubicin,
cyclophosphamide, bleomycin, vincristine, and
prednisone) and involved field radiotherapy:
result of a Gruppo Italiano Multiregionale per
lo Studio dei Linfomi e Leucenie (GIMURELL)
study. ::READ
MORE::
Prognostic significance of mid- and post-ABVD
PET imaging in Hodgkin's lymphoma: the
importance of involved-field radiotherapy. ::READ
MORE::
Vincristine sulfate liposomes injection
(Marqibo) in heavily pretreated patients with
refractory aggressive non-Hodgkin lymphoma:
report of the Pivotal Phase 2 Study. ::READ
MORE::
>Back to the
top
| |
Selected
Trials
A Phase 1-2, Multicenter, Open-Label Study of
AEG35156 in Patients with Relapsed or Refractory
Chronic Lymphocytic Leukemia and Indolent B-Cell
Lymphomas ::READ
MORE::
Phase II Study of Oral Panobinostat in Adult
Patients with Relapsed/Refractory Classical
Hodgkin's Lymphoma ::READ
MORE::
Phase III Study of Bendamustine Hydrochloride
and Rituximab (BR) Compared with R-CVP or R-CHOP
in the First-Line Treatment of Patients with
Advanced Indolent Non-Hodgkin's Lymphoma (NHL)
or Mantle Cell Lymphoma (MCL) ::READ
MORE::
A Phase III Study of Galiximab + Rituximab
versus Rituximab + Placebo in Follicular
Non-Hodgkin's Lymphoma (NHL) ::READ
MORE::
Phase II: Liposomal Doxorubicin Followed by
Bexarotene in Treating Patients with Cutaneous
T-Cell Lymphoma ::READ
MORE::
>Back to the
top
| |
| IRC
Question of
the Month | 
Q: I am
being treated for lymphoma. What should I know
about flu shots?
A: According to the US
Centers for Disease Control and Prevention
(CDC), approximately 83 percent of the US
population is specifically recommended for
annual vaccination against seasonal influenza.
Chief medical officer at LLS, Barton Kamen, MD,
PhD says "Seasonal flu shots are recommended for
cancer survivors and anyone who has contact with
a cancer patient. The ideal time to be
vaccinated for seasonal flu is in the fall. Keep
in mind that it takes about two weeks for the
shot to begin providing protection. Before you
get the shot let your doctor know about any
allergies you have and any previous reactions to
a flu shot."
In general, patients undergoing cancer
treatment are advised to receive a flu shot
rather than the nasal mist form of the flu
vaccine. Shots are safe for people with
compromised immune systems because they are made
from inactivated virus; the flu mist is made
from a live virus. For cancer patients who have
had a stem cell transplant, guidelines
established by the CDC and the American Society
for Blood & Marrow Transplantation (ASBMT)
recommend flu shots for all bone marrow, stem
cell and cord blood transplant survivors
beginning one-year post-transplant and
continuing every year thereafter. The flu shot
is also recommended for others living or working
in the household. Although most transplant
centers follow the current CDC guidelines
regarding flu shots, some recommend flu shots
even earlier than one year post-transplant. For
more information about recommended vaccinations
after transplant from the Center for
International Blood and Marrow Transplant
Research click
here.
A type of flu virus called "novel influenza A
(H1N1)" and also referred to as "swine flu" was
first detected in people in the United States in
April 2009. It is spread from person-to-person,
probably in a similar way as regular seasonal
flu viruses. Recently, the CDC's Advisory
Committee on Immunization Practices (ACIP)
issued guidelines regarding the use of vaccine
against infection with novel influenza A (H1N1)
virus. The guidelines are intended to provide
healthcare providers and the public with
information about the population groups who are
recommended to be first to receive the H1N1 2009
vaccine. The licensed H1N1 vaccine is expected
to be available by mid-October 2009.
The CDC says that all persons, including
those older than 65 years of age, who are
currently recommended for seasonal influenza
vaccine, should receive the seasonal vaccine as
soon as it is available. In addition, persons
aged 25 to 64 years who are at greater risk for
influenza-related complications because of
underlying medical conditions, pregnant women,
household contacts or caregivers for infants
younger than 6 months, healthcare and emergency
medical services personnel, children and young
adults 6 months to 24 years of age, comprise the
general population groups that should be
targeted as an initial focus of vaccination
efforts. Inactivated vaccines against
seasonal flu and H1N1 viruses may be
administered at the same time, using different
injection sites on the body.
The medical conditions that increase the risk
for flu-related complications include
- Hematologic, renal, hepatic, cognitive,
neurologic/neuromuscular, or metabolic
disorders, including diabetes;
- Immunosuppression caused by medications or
by human immunodeficiency virus
- Chronic pulmonary conditions, including
asthma; cardiovascular conditions except for
hypertension.
Although the H1N1 vaccine is not available
yet, there are steps you can take to help
prevent the spread of germs that cause
respiratory illnesses like the flu. For more
information on the H1N1 virus click
here. The CDC recommendations for seasonal
flu are available at the CDC
Web page.
Please call our
Information Resource Center (IRC) to speak with
a trained information specialist. IRC staff are
available Monday through Friday, 9 a.m. to 6
p.m. ET, toll free at (800) 955-4572. Contact us
online or click the "Live
Patient Help" button on the www.LLS.org
homepage.
> Back to the
top
| |
| | | |
|
|
 |
Supported by an
unrestricted
educational grant
from
 |
 |
|
Contact Us: The
Leukemia & Lymphoma Society, 1311 Mamaroneck
Ave., White Plains, NY 10605, (800)
955-4572
|
|
| Visit our e-Store
& Special Offers page where you can
support businesses that support
LLS. | | | | | |
|
| | | |
